These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 10727544

  • 1. Altered IgG(4) renal clearance in patients with inflammatory bowel diseases. Evidence for a subclinical impairment of protein charge renal selectivity.
    Monteleone G, Cristina G, Parrello T, Morano S, Biancone L, Pietravalle P, Sagratella E, Doldo P, Luzza F, Di Mario U, Pallone F.
    Nephrol Dial Transplant; 2000 Apr; 15(4):498-501. PubMed ID: 10727544
    [Abstract] [Full Text] [Related]

  • 2. Charge selectivity of proteinuria in type I diabetes explored by Ig subclass clearance.
    Pietravalle P, Morano S, Cristina G, De Rossi MG, Mariani G, Cotroneo P, Ghirlanda G, Clementi A, Andreani D, Di Mario U.
    Diabetes; 1991 Dec; 40(12):1685-90. PubMed ID: 1756909
    [Abstract] [Full Text] [Related]

  • 3. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy.
    Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ.
    Aliment Pharmacol Ther; 2001 Aug; 15(8):1131-7. PubMed ID: 11472315
    [Abstract] [Full Text] [Related]

  • 4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F, Polymeros D, Panagiotou M, Theodoropoulos K, Rigopoulos D.
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [Abstract] [Full Text] [Related]

  • 5. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
    Bansi DS, Chapman RW, Fleming KA.
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
    [Abstract] [Full Text] [Related]

  • 6. Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.
    Horton N, Wu X, Philpott J, Garber A, Achkar JP, Brzezinski A, Lashner BA, Shen B.
    Dig Dis Sci; 2016 Nov; 61(11):3270-3277. PubMed ID: 27619393
    [Abstract] [Full Text] [Related]

  • 7. Measurement of glomerular charge selectivity in non-diabetic renal disease.
    Hemmelder MH, de Zeeuw D, de Jong PE.
    Nephrol Dial Transplant; 1997 Nov; 12 Suppl 2():57-62. PubMed ID: 9269702
    [Abstract] [Full Text] [Related]

  • 8. A charge selectivity impairment in protein permselectivity is present in type 2 diabetes.
    Morano S, Pietravalle P, De Rossi MG, Mariani G, Cristina G, Medici F, Sensi M, Andreani D, Di Mario U.
    Acta Diabetol; 1993 Nov; 30(3):138-42. PubMed ID: 8111073
    [Abstract] [Full Text] [Related]

  • 9. Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course.
    Paul S, Boschetti G, Rinaudo-Gaujous M, Moreau A, Del Tedesco E, Bonneau J, Presles E, Mounsef F, Clavel L, Genin C, Flourié B, Phelip JM, Nancey S, Roblin X.
    J Crohns Colitis; 2015 Jun; 9(6):445-51. PubMed ID: 25895876
    [Abstract] [Full Text] [Related]

  • 10. Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?
    Poulou AC, Goumas KE, Dandakis DC, Tyrmpas I, Panagiotaki M, Georgouli A, Soutos DC, Archimandritis A.
    World J Gastroenterol; 2006 Feb 07; 12(5):739-46. PubMed ID: 16521187
    [Abstract] [Full Text] [Related]

  • 11. Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens.
    Sugi K, Saitoh O, Matsuse R, Tabata K, Uchida K, Kojima K, Nakagawa K, Tanaka S, Teranishi T, Hirata I, Katsu K.
    Am J Gastroenterol; 1999 May 07; 94(5):1304-12. PubMed ID: 10235211
    [Abstract] [Full Text] [Related]

  • 12. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
    Qiu X, Ma J, Wang K, Zhang H.
    Oncotarget; 2017 Jan 03; 8(1):1031-1045. PubMed ID: 27906680
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
    Mulder CJ, van den Hazel SJ.
    Mediators Inflamm; 1998 Jan 03; 7(3):135-6. PubMed ID: 9705596
    [Abstract] [Full Text] [Related]

  • 15. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study.
    Gisbert JP, Luna M, González-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Maté J.
    Gastroenterol Hepatol; 2008 Oct 03; 31(8):477-84. PubMed ID: 18928745
    [Abstract] [Full Text] [Related]

  • 16. Microalbuminuria is associated with impaired glomerular permselectivity in lymphoma patients.
    Pedersen LM, Johnsen HE.
    Scand J Clin Lab Invest; 2005 Oct 03; 65(6):477-84. PubMed ID: 16179280
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease.
    Wiersma H, Escher JC, Dilger K, Trenk D, Benninga MA, van Boxtel CJ, Taminiau J.
    Inflamm Bowel Dis; 2004 Sep 03; 10(5):626-31. PubMed ID: 15472525
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
    Cheddani H, Dauchet L, Fumery M, Charpentier C, Marie Bouvier A, Dupas JL, Pariente B, Peyrin-Biroulet L, Savoye G, Gower-Rousseau C.
    Am J Gastroenterol; 2016 Oct 03; 111(10):1428-1436. PubMed ID: 27481308
    [Abstract] [Full Text] [Related]

  • 20. Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment.
    Siddique I, Hasan F, Khan I.
    Scand J Gastroenterol; 2009 Oct 03; 44(1):56-64. PubMed ID: 18785066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.